The Protein Is Isolated Or Extracted From Milk Patents (Class 800/7)
  • Patent number: 9511087
    Abstract: In one aspect, the disclosure provides methods of suppressing blood clotting and/or preventing hemorrhage in a subject having extracorporeal membrane oxygenation comprising administering antithrombin. In some embodiments, the antithrombin used in the methods disclosed herein is ATryn®.
    Type: Grant
    Filed: August 2, 2013
    Date of Patent: December 6, 2016
    Assignee: rEVO Biologics, Inc.
    Inventors: Johan Frieling, Simon Lowry
  • Publication number: 20130131317
    Abstract: The invention features a process of expressing secreted recombinant human alpha-fetoprotein (rHuAFP) in the milk or urine of transgenic mammals.
    Type: Application
    Filed: January 25, 2013
    Publication date: May 23, 2013
    Applicant: Merrimack Pharmaceuticals, Inc.
    Inventor: Merrimack Pharmaceuticals, Inc.
  • Publication number: 20130053546
    Abstract: The invention relates to the production of recombinant human fibrinogen (rhFib) in the milk of transgenic mammalian animals. This production and subsequent purification process is generally hampered by the occurrence of so-called ‘clots’ and ‘flakes’ in the milk which, in severe cases, may prevent the cow from being milked at all, resulting in a halt of lactation. These clots and flakes occur because of the expression of the fibrinogen protein, which is a factor that is normally involved in blood clotting. The invention relates to solving this milk clotting problem by treating the (lactating) animals with anticoagulants such as coumarins. A preferred anticoagulant that is used in the methods of the present invention is warfarin.
    Type: Application
    Filed: March 11, 2011
    Publication date: February 28, 2013
    Applicant: PHARMING INTELLECTUAL PROPERTY BV
    Inventors: Kathryn Margaret Nelson, Michael William Mosesson, Anthony Pusateri, Erik Jordahl Forsberg
  • Patent number: 8343761
    Abstract: An objective of the present invention is to facilitate the acquisition of antibody-producing cells that are infiltrating virus-infected cells, cancer cells, abnormal cells forming a benign hyperplasia, and the like, and to improve the efficiency of the production of antibodies as well as nucleic acids encoding them from the antibody-producing cells. The present inventors discovered that, when cancer tissues comprising infiltrating lymphocytes are transplanted into highly immunodeficient animals that do not have T cells, B cells, and NK cells and further exhibit a low IFN production ability, the differentiation and proliferation of infiltrating lymphocytes are unexpectedly promoted, and the number of plasma cells that produce antibodies recognizing cancer tissues increases dramatically, plasma cells can be separated easily, and antibodies or nucleic acids encoding them can be easily prepared from the plasma cells.
    Type: Grant
    Filed: July 21, 2011
    Date of Patent: January 1, 2013
    Assignees: Chugai Seiyaku Kabushiki Kaisha, Pharmalogicals Research Pte. Ltd., CIEA International Inc.
    Inventors: Masayuki Tsuchiya, Masami Suzuki, Kenji Yoshida, Etsuko Fujii, Miho Watanabe, Koichi Matsubara, Yu Jau Chen, Juliana Sim
  • Publication number: 20120259093
    Abstract: The invention features a process of expressing secreted recombinant human alpha-fetoprotein (rHuAFP) in the milk or urine of transgenic mammals.
    Type: Application
    Filed: April 13, 2012
    Publication date: October 11, 2012
    Applicant: Merrimack Pharmaceuticals, Inc.
    Inventors: Stace LINDSAY, Robert Mulroy, Daniel Semeniuk
  • Patent number: 8030538
    Abstract: The present invention relates to a bovine beta-casein gene targeting vector comprising (1) a first region having a length of 5 to 12 kb which is homologous to the promoter and its flanking nucleic acid sequences of bovine beta-casein gene, and comprising exon 1, intron 1, and exon 2 of bovine beta-casein gene; (2) a region for cloning a nucleic acid coding for desired proteins; (3) a region for coding a positive selection marker; (4) a second region having a length of 2.8 to 3.5 kb which is homologous to the nucleic acid sequences of bovine beta-casein gene, and comprising exon 5, 6, 7 and 8, and intron 5, 6 and 7 of bovine beta-casein gene; wherein the nucleic acid segment corresponding to the first region is located upstream to the nucleic acid segment corresponding to the second region in the 5?-3? arrangement of beta-casein gene.
    Type: Grant
    Filed: November 18, 2005
    Date of Patent: October 4, 2011
    Assignee: Korea Research Institute of Bioscience and Biotechnology
    Inventors: Yong-Mahn Han, Kyung-Kwang Lee, Mira Chang, Deog-Bon Koo
  • Publication number: 20110239314
    Abstract: The present invention relates to a porcine alpha-S1-casein gene, a porcine alpha-S1-casein gene promoter, an expression comprising the same promoter, and a method for the production of a target protein using the same expression vector. The promoter of the present invention facilitates the mammary gland-specific expression of the target protein. Accordingly, an animal transformed with the promoter secretes the target protein in milk at high concentration, and thus can be advantageously used for the production of useful proteins.
    Type: Application
    Filed: June 29, 2009
    Publication date: September 29, 2011
    Inventors: Myeong Goo Yeo, Sung-Jo Kang, Jong Deok Ahn
  • Publication number: 20110209229
    Abstract: The present invention provides a porcine beta-casein gene, a porcine beta-casein gene promoter, an expression vector comprising the same promoter, and a method for the production of a target protein using the same expression vector. The promoter of the present invention facilitates mammary gland-specific expression of the target protein and therefore can be useful for high-concentration production of beneficial proteins in milk.
    Type: Application
    Filed: December 31, 2008
    Publication date: August 25, 2011
    Inventors: Jin Hoi Kim, Myeong Goo Yeo, Sung-Jo Kang, Jong Deok Ahn
  • Publication number: 20110162094
    Abstract: Modified factors VII/VIIa with a high stability, nucleic acids encoding such modified factors VII/VIIa, and methods of preparing the same.
    Type: Application
    Filed: June 12, 2008
    Publication date: June 30, 2011
    Applicant: LFB BIOTECHNOLOGIES
    Inventors: Emmanuel Nony, Sami Chtourou, Nicolas Bihoreau
  • Patent number: 7928285
    Abstract: In general, the invention features genetically modified non-human mammals (e.g., bovines and other ungulates), and methods of making these mammals. In particular, the invention features transgenic ungulates having reduced levels of endogenous IgM heavy chain and/or prion protein.
    Type: Grant
    Filed: June 25, 2008
    Date of Patent: April 19, 2011
    Assignee: Kyowa Hakko Kirin Co., Ltd.
    Inventors: James M. Robl, Yoshimi Kuroiwa, Poothappillai Kasinathan, Isao Ishida, Kazuma Tomizuka
  • Publication number: 20110077208
    Abstract: The invention features a process of expressing secreted recombinant human alpha-fetoprotein (rHuAFP) in the milk or urine of transgenic mammals.
    Type: Application
    Filed: May 28, 2010
    Publication date: March 31, 2011
    Applicant: Merrimack Pharmaceuticals, Inc.
    Inventors: Stace Lindsay, Robert Mulroy, Daniel Semeniuk
  • Publication number: 20110072526
    Abstract: The invention relates to a method of producing a protein of interest, comprising making a non-human transgenic mammal that produces said protein in its milk, obtaining said milk from the non-human transgenic mammal and purifying said protein of interest from the milk. Transgenic bovine animals were generated, which are able to produce human growth hormone in mammary glands. The method involves cloning of a genetic construct comprising the hGH gene and beta casein promoter sequences conveniently in an expression vector. It also includes transfection procedures into fetal bovine somatic cells, generally fibroblasts, and the nuclear transfer into enucleated bovine oocytes, generating thus transgenic embryos.
    Type: Application
    Filed: May 17, 2010
    Publication date: March 24, 2011
    Applicant: Sterrenbeld Biotechnologie North America, Inc.
    Inventors: Carlos Alberto Melo, Lino Baranao, Cesar Horacio Carbonetto
  • Publication number: 20110067122
    Abstract: The present invention relates to the production of a transgenic ungulate which comprises a genetic modification that results in inactivation and loss of expression of its endogenous antibodies, and the expression of xenogenous antibodies, preferably human antibodies. This is effected by inactivation of the IgM heavy chain expression and, optionally, by inactivation of the Ig light chain expression, and by the further introduction of an artificial chromosome which results in the expression of non-bovine antibodies, preferably human antibodies.
    Type: Application
    Filed: February 9, 2009
    Publication date: March 17, 2011
    Applicant: Kyowa Hakko Kirin Co., Ltd.
    Inventors: James M. Robl, Richard A. Goldsby, Stacy E. Ferguson, Yoshimi Kuroiwa, Kazuma Tomizuka, Isao Ishida, Barbara A. Osborne
  • Patent number: 7888321
    Abstract: A non-human transgenic mammalian animal, as described above, contains an exogenous double stranded DNA sequence stably integrated into the genome of the animal, which comprises cis-acting regulatory units operably linked to a DNA sequence encoding human FIX protein without the benefit of the presence of a complete milk gene sequence for gene rescue, and a signal sequence is active in directing newly expressed Factor IX into the milk of the animal at levels in an unactivated form that is suitable for subsequent processing for therapeutic applications in treating Hemophilia B. The transgenic mammals are preferably pigs, cows, sheep, goats and rabbits. The applications include milk derivatives for oral delivery and oral tolerization in the treatment of Hemophilia B.
    Type: Grant
    Filed: October 21, 2008
    Date of Patent: February 15, 2011
    Assignee: Progenetics LLC
    Inventors: Julian D. Cooper, William Hugold Velander, Tanya K. O'Sickey
  • Patent number: 7871793
    Abstract: Compositions useful for inhibiting the growth of bacteria, including bacteria that can cause gastric ulcers, are provided. In addition, transgenic organism that can produce such compositions are provided. Methods of using the compositions to treat or prevent gastric ulcers in a subject, including a human subject, also are provided.
    Type: Grant
    Filed: February 18, 2005
    Date of Patent: January 18, 2011
    Assignee: Burnham Institute for Medical Research
    Inventors: Jun Nakayama, Masatomo Kawakubo, Minoru Fukuda, Tsutomu Katsuyama
  • Publication number: 20100293623
    Abstract: The invention concerns a method for producing non-human mammal embryos, in particular rabbit by nuclear cloning. The invention also concerns the mammals obtained and their uses.
    Type: Application
    Filed: April 15, 2009
    Publication date: November 18, 2010
    Applicant: Institut National de la Recherche Agronomique
    Inventors: Patrick Chesne, Pierre Adenot, Jean-Paul Renard
  • Patent number: 7807862
    Abstract: The invention relates to a method of producing a protein of interest, comprising making a non-human transgenic mammal that produces said protein in its milk, obtaining said milk from the non-human transgenic mammal and purifying said protein of interest from the milk. Transgenic bovine animals were generated, which are able to produce human growth hormone in mammary glands. The method involves cloning of a genetic construct encoding hGH gene and beta casein promoter conveniently in an expression vector. It also includes transfection procedures into fetal bovine somatic cells, generally fibroblasts, and the nuclear transfer into enucleated bovine oocytes, generating thus transgenic embryos.
    Type: Grant
    Filed: September 29, 2004
    Date of Patent: October 5, 2010
    Assignee: Sterrenbeld Biotechnologie North America, Inc.
    Inventors: Carlos Alberto Melo, Lino Baranao
  • Publication number: 20100205680
    Abstract: The present invention provides a mammary gland-specific human erythropoietin expression (hEPO) vector, transgenic animal and method for producing human erythropoietin using the same. The inventive hEPO-expressing transgenic animals express a mammary gland-specific EPO at an extremely higher concentration than the convention method. The hEPO produced from inventive transgenic animals shows better stability and superior physiological activity than those of the same kind of commerally available protein. Therefore, the inventive hEPO-expressing transgenic animals can be effectively used for production of EPO showing a superior physiological activity than the existing EPO.
    Type: Application
    Filed: August 8, 2007
    Publication date: August 12, 2010
    Inventor: Jin Hoi Kim
  • Publication number: 20100162418
    Abstract: A pharmaceutical agent for treating a disease such as inflammatory diseases, blood coagulation diseases associated with deficiency of Protein S has been required. The present invention provides a Protein S composition comprising recombinant Protein S molecules having complex type N-glycoside-linked sugar chains, wherein the Protein S has a higher binding activity to a receptor for advanced glycation end products (hereinafter referred to as “RAGE”) than native Protein S present in healthy human blood, and also has a higher ratio of sugar chains in which fucose is not bound to the complex type N-glycoside-linked sugar chains bound to Protein S than native Protein S present in healthy human blood.
    Type: Application
    Filed: August 13, 2009
    Publication date: June 24, 2010
    Applicant: KYOWA HAKKO KIRIN CO., LTD.
    Inventors: Yutaka KANDA, Hiroshi SATO, Tsuyoshi YAMADA, Akifumi KATO, Mitsuo SATOH
  • Publication number: 20100125918
    Abstract: The invention provides a new type of a capsid protein VP1 of human enterovirus 71, named as MEL701-VP1 and functional/structural variants thereof, which is used for protection against enterovirus. The transgenic animal producing the protein, the composition comprising the protein and the method for production thereof are also provided.
    Type: Application
    Filed: November 19, 2008
    Publication date: May 20, 2010
    Applicant: National Chung Hsing University
    Inventors: Chuan-Mu Chen, Hsiao-Ling Chen
  • Patent number: 7718845
    Abstract: The invention relates to a method of producing a protein of interest, comprising making a non-human transgenic mammal that produces said protein in its milk, obtaining said milk from the non-human transgenic mammal and purifying said protein of interest from the milk. Transgenic bovine animals were generated, which are able to produce human growth hormone in mammary glands. The method involves cloning of a genetic construct encoding hGH gene and beta casein promoter conveniently in an expression vector. It also includes transfection procedures into fetal bovine somatic cells, generally fibroblasts, and the nuclear transfer into enucleated bovine oocytes, generating thus transgenic embryos.
    Type: Grant
    Filed: September 29, 2004
    Date of Patent: May 18, 2010
    Assignee: Sterrenbeld Biotechnologie North America, Inc.
    Inventors: Carlos Alberto Melo, Lino Baranao, Cesar Horacio Carbonetto
  • Publication number: 20100024047
    Abstract: Transgenic and cloned ungulates and particularly cloned cattle are disclosed, wherein such cattle contain a deletion or disruption of the prion gene locus and do not express functional prion protein, and are not susceptible to prion-related diseases such as bovine spongiform encephalopy or Mad Cow Disease.
    Type: Application
    Filed: July 9, 2007
    Publication date: January 28, 2010
    Inventors: Deborah J. Good, Jose Cibelli
  • Patent number: 7632980
    Abstract: The invention provides modified recombinant nucleic acid sequences (preferably DNA) and methods for increasing the mRNA levels and protein expression of proteins which are known to be, or are likely to be, difficult to express in cell culture systems, mammalian cell culture systems, or in transgenic animals. The preferred “difficult” protein candidates for expression using the recombinant techniques of the invention are those proteins derived from heterologous cells preferably those of lower organisms such as parasites, bacteria, and virus, having DNA coding sequences comprising high overall AT content or AT rich regions and/or mRNA instability motifs and/or rare codons relative to the recombinant expression system to be used.
    Type: Grant
    Filed: October 20, 1998
    Date of Patent: December 15, 2009
    Assignee: GTC Biotherapeutics, Inc.
    Inventors: Li How Chen, Harry Meade
  • Publication number: 20090221492
    Abstract: Recombinant Factor IX characterized by a high percentage of active protein can be obtained in the milk of transgenic animals that incorporate chimeric DNA molecules according to the present invention. Transgenic animals of the present invention are produced by introducing into developing embryos DNA that encodes Factor IX, such that the foreign DNA is stably incorporated in the DNA of germ line cells of the mature animal. Particularly efficient expression was accomplished using a chimeric construct comprising a mammary gland specific promoter, Factor IX cDNA that lacked the complete or any portion of the 5?-untranslated and 3?-untranslated region, which is substituted with a 5-? and 3?-end of the mouse whey acidic protein gene. In vitro cell cultures of cells explanted from the transgenic mammal of the invention and methods of producing Factor IX from such said culture and methods of treating hemophilia B are also described.
    Type: Application
    Filed: August 29, 2008
    Publication date: September 3, 2009
    Inventors: William H. Velander, William N. Drohan, Henryk Lubon, John L. Johnson, Mary Ann H. Johnson
  • Publication number: 20090222935
    Abstract: In general, the invention features genetically modified non-human mammals (e.g., bovines and other ungulates), and methods of making these mammals. In particular, the invention features transgenic ungulates having reduced levels of endogenous IgM heavy chain and/or prion protein.
    Type: Application
    Filed: June 25, 2008
    Publication date: September 3, 2009
    Inventors: James M. Robl, Yoshimi Kuroiwa, Poothappillai Kasinathan, Isao Ishida, Kazuma Tomizuka
  • Publication number: 20090187999
    Abstract: The invention relates to a non-human transgenic mammal that is useful for the production of a protein of interest that may be toxic to the mammal. The mammal is characterized by the fact that it is transgenic for the production in its milk of an inactive form of the protein of interest, preferably recombinant human insulin. It is not possible to produce recombinant human insulin in transgenic mammals since this molecule has a certain degree of biological activity in the mammals and could be toxic to the mammal. Thus, the invention involves cloning a genetic construct comprising a sequence encoding a modified human insulin precursor under the control of a beta casein promoter in an expression vector. It also involves transfecting the expression plasmid into fetal bovine somatic cells, such as fibroblasts, and enucleating bovine oocytes by nuclear transfer to generate transgenic embryos.
    Type: Application
    Filed: June 13, 2008
    Publication date: July 23, 2009
    Applicant: Sterrenbeld Biotechnologie North America, Inc.
    Inventors: A. BERCOVICH, A. Prync, C. Melo, N. Fernandez, N. Judewicz, M. Criscuolo
  • Patent number: 7544853
    Abstract: The present invention relates to the use of a C1 inhibitor (C1INH) with shorter half-life than plasma-derived C1INH for the preparation of a medicament for the transient treatment of an individual. It relates to both therapeutic and prophylactic treatment. The method of the invention allows for the administration of C1INH at certain therapeutic levels for a concise pre-determined time span. Pharmaceutical compositions based on C1INH with shorter half-lives may be used both in situations where transient treatment is merely and advantage. The advantage of the use according to the invention is that an individual is not exposed to C1INH for longer than required, since the levels of the C1INH more rapidly subsides after administration has stopped. In contrast, levels of plasma-derived C1INH would remain elevated for a prolonged period of time.
    Type: Grant
    Filed: May 14, 2004
    Date of Patent: June 9, 2009
    Assignee: Pharming Intellectual Property B.V.
    Inventor: Johannes Henricus Nuijens
  • Patent number: 7531325
    Abstract: An improved method for recovering recombinantly produced polypeptides is described. The method involves expressing the recombinant polypeptide as a fusion protein with a pro-peptide. The pro-peptide-polypeptide fusion protein can be cleaved and the recombinant polypeptide released under the appropriate conditions.
    Type: Grant
    Filed: December 19, 2002
    Date of Patent: May 12, 2009
    Assignee: SemBioSys Genetics Inc.
    Inventors: Gijs Van Rooijen, Joenel Alcantara, Maurice M. Moloney
  • Patent number: 7501553
    Abstract: The invention provides modified recombinant nucleic acid sequences (preferably DNA) and methods for increasing the mRNA levels and protein expression of malarial surface protein MSP-1 which is known to be difficult to express in cell culture systems, mammalian cell culture systems, or in transgenic animals. The preferred protein candidates for expression using the recombinant techniques of the invention are MSP-1 proteins expressed from DNA coding sequences comprising reduced overall AT content or AT rich regions and/or mRNA instability motifs and/or rare codons relative to the native MSP-1 gene.
    Type: Grant
    Filed: February 20, 2002
    Date of Patent: March 10, 2009
    Assignee: GTC Biotherapeutics, Inc.
    Inventors: Li-How Chen, Harry M. Meade
  • Patent number: 7501265
    Abstract: An improved method for recovering recombinantly produced polypeptides is described. The method involves expressing the recombinant polypeptide as a fusion protein with a pro-peptide. The pro-peptide-polypeptide fusion protein can be cleaved and the recombinant polypeptide released under the appropriate conditions.
    Type: Grant
    Filed: April 23, 1998
    Date of Patent: March 10, 2009
    Assignee: SemBioSys Genetics Inc.
    Inventors: Maurice Moloney, Joenel Alcantara, Gijs Van Rooijen
  • Publication number: 20090013419
    Abstract: The present invention relates to a bovine beta-casein gene targeting vector comprising (1) a first region having a length of 5 to 12 kb which is homologous to the promoter and its flanking nucleic acid sequences of bovine beta-casein gene, and comprising exon 1, intron 1, and exon 2 of bovine beta-casein gene; (2) a region for cloning a nucleic acid coding for desired proteins; (3) a region for coding a positive selection marker; (4) a second region having a length of 2.8 to 3.5 kb which is homologous to the nucleic acid sequences of bovine beta-casein gene, and comprising exon 5, 6, 7 and 8, and intron 5, 6 and 7 of bovine beta-casein gene; wherein the nucleic acid segment corresponding to the first region is located upstream to the nucleic acid segment corresponding to the second region in the 5?-3? arrangement of beta-casein gene.
    Type: Application
    Filed: November 18, 2005
    Publication date: January 8, 2009
    Applicant: KOREA RESEARCH INSTITUTE OF BIOSCIENCE & BIOTECHNOLOGY
    Inventors: Yong-Mahn Han, Kyung-Kwang Lee, Mira Chang, Deog-Bon Koo
  • Patent number: 7435869
    Abstract: A transgenic, non-human mammalian animal is capable of expressing a heterologous gene for human or other recombinant physiologically functional fibrinogen holoprotein or individual subunit chain polypeptides thereof or a modified or fusion fibrinogen in mammary glands of the animals and secreting the expressed product into a body fluid. Methodology employing such a mammal yields recombinant physiologically functional fibrinogens, subunit chain polypeptides thereof, and modified or fusion fibrinogens.
    Type: Grant
    Filed: January 24, 2005
    Date of Patent: October 14, 2008
    Assignees: Virgina Tech. Intellectual Properties, Inc., American National Red Cross, University of North Carolina at Chapel Hill
    Inventors: William H. Velander, William N. Drohan, Henryk Lubon, John L. Johnson
  • Publication number: 20080235815
    Abstract: Methods and compositions for the administration of transposon-based vectors to the reproductive organs of animals and the creation of transgenic animals. Preferred methods involve administration of the transposon-based vectors to the lumen of the oviduct of an avian, expression of a vector derived transgene in the avian, and deposition of the resultant polypeptide in an egg. This invention allows for large amounts of protein to be deposited in the egg.
    Type: Application
    Filed: October 31, 2007
    Publication date: September 25, 2008
    Inventors: Richard K. Cooper, William C. Fioretti, Gary G. Cadd
  • Publication number: 20080220002
    Abstract: Modified fission proteins of transferrin and therapeutic proteins or peptides, preferably antibody variable regions, with increased serum half-life or serum stability are disclosed. Preferred fusion proteins include those modified so that the transferrin moiety exhibits no or reduced glycosylation, binding to iron and/or binding to the transferrin receptor.
    Type: Application
    Filed: April 3, 2007
    Publication date: September 11, 2008
    Inventors: Homayoun Sadeghi, Christopher P. Prior, Andrew Turner
  • Patent number: 7419948
    Abstract: Recombinant Factor IX characterized by a high percentage of active protein can be obtained in the milk of transgenic animals that incorporate chimeric DNA molecules according to the present invention. Transgenic animals of the present invention are produced by introducing into developing embryos DNA that encodes Factor IX, such that the foreign DNA is stably incorporated in the DNA of germ line cells of the mature animal. Particularly efficient expression was accomplished using a chimeric construct comprising a mammary gland specific promoter, Factor IX cDNA that lacked the complete or any portion of the 5?-untranslated and 3?-untranslated region, which is substituted with a 5-? and 3?-end of the mouse whey acidic protein gene. In vitro cell cultures of cells explanted from the transgenic mammal of the invention and methods of producing Factor IX from such said culture and methods of treating hemophilia B are also described.
    Type: Grant
    Filed: April 29, 2005
    Date of Patent: September 2, 2008
    Assignees: American Red Cross, Virginia Tech Intellectual Properties, Inc.
    Inventors: William H. Velander, William N. Drohan, Henryk Lubon, Mary Ann H. Johnson, legal representative, John L. Johnson
  • Patent number: 7381712
    Abstract: The present invention provides for methods of producing transgenic avians which may include delivering a heterologous nucleic acid to oviduct tissue of an avian wherein the nucleic acid enters a cell of the oviduct tissue and is expressed.
    Type: Grant
    Filed: May 10, 2004
    Date of Patent: June 3, 2008
    Assignee: AviGenics, Inc.
    Inventors: Leandro Christmann, Markley C. Leavitt, Dawn M. Eberhardt, Timalynn M. Matthews
  • Publication number: 20080118501
    Abstract: The invention relates, in part, to antibodies with increased ADCC activity. Methods of producing such antibodies are also provided. The antibodies of the invention are produced in mammary epithelial cells, such as those in a non-human transgenic animal engineered to express and secrete the antibody in its milk. The antibodies or compositions comprising the antibodies can be used to treat disease in which ADCC activity provides a benefit. In one embodiment, therefore, the antibodies or compositions comprising the antibodies can be used to treat cancer, lymphoproliferative disease or autoimmune disease.
    Type: Application
    Filed: October 23, 2006
    Publication date: May 22, 2008
    Applicant: GTC Biotherapeutics, Inc.
    Inventors: Daniel Schindler, Harry M. Meade, Timothy Edmunds, John McPherson
  • Patent number: 7354594
    Abstract: The invention provides modified recombinant nucleic acid sequences (preferably DNA) and methods for increasing the mRNA levels and protein expression of malarial surface protein MSP-1 which is known to be difficult to express in cell culture systems, mammalian cell culture systems, or in transgenic animals. The preferred protein candidates for expression using the recombinant techniques of the invention are MSP-1 proteins expressed from DNA coding sequences comprising reduced overall AT content or AT rich regions and/or mRNA instability motifs and/or rare codons relative to the native MSP-1 gene.
    Type: Grant
    Filed: May 27, 2005
    Date of Patent: April 8, 2008
    Assignee: GTC Biotherapeutics, Inc.
    Inventors: Li How Chen, Harry M. Meade
  • Publication number: 20080026072
    Abstract: Compositions useful for inhibiting the growth of bacteria, including bacteria that can cause gastric ulcers, are provided. In addition, transgenic organism that can produce such compositions are provided. Methods of using the compositions to treat or prevent gastric ulcers in a subject, including a human subject, also are provided.
    Type: Application
    Filed: February 18, 2005
    Publication date: January 31, 2008
    Inventors: Jun Nakayama, Masatomo Kawakubo, Minoru Fukuda, Tsutomu Katsuyama
  • Patent number: 7271312
    Abstract: The invention provides modified recombinant nucleic acid sequences (preferably DNA) and methods for increasing the mRNA levels and protein expression of proteins which are known to be, or are likely to be, difficult to express in cell culture systems, mammalian cell culture systems, or in transgenic animals. The preferred “difficult” protein candidates for expression using the recombinant techniques of the invention are those proteins derived from heterologous cells preferably those of lower organisms such as parasites, bacteria, and virus, having DNA coding sequences comprising high overall AT content or AT rich regions and/or mRNA instability motifs and/or rare codons relative to the recombinant expression system to be used.
    Type: Grant
    Filed: October 20, 1998
    Date of Patent: September 18, 2007
    Assignee: GTC Biotherapeutics, Inc.
    Inventors: Li How Chen, Harry Meade
  • Patent number: 7220718
    Abstract: Disclosed herein is a simple method for the treatment of antigen-deficiency diseases, by orally administering to a subject a therapeutically effective amount of the deficient antigen, wherein the antigen is not present in a liposome. In one embodiment, the method increases hemostasis in a subject having hemophilia A or B, by orally administering to the hemophiliac a therapeutically effective amount of the appropriate clotting factor other than in a liposome, sufficient to induce oral tolerance and supply exogenous clotting factor to the subject.
    Type: Grant
    Filed: August 2, 2002
    Date of Patent: May 22, 2007
    Assignees: United States of America as represented by the Secretary of the Department of Health and Human Services, Virginia Tech Intellectual Properties, Inc.
    Inventors: Oral Alpan, Tirumalai Kamala, Polly Matzinger, William Hugold Velander
  • Patent number: 7169963
    Abstract: The present invention relates to animals that express exogenous growth factors in their milk, and in particular to pigs that express exogenous IGF-I in their milk. The present invention also relates to methods for increasing piglet weight gain and intestinal lactase activity. The present invention thus provides a method of facilitating piglet development and decreasing piglet mortality.
    Type: Grant
    Filed: September 30, 2003
    Date of Patent: January 30, 2007
    Assignee: Board of Trustees of the University of Illinois
    Inventors: Matthew B. Wheeler, Sharon M. Donovan, Gregory T. Bleck, Marcia Monaco-Siegel
  • Patent number: 7157615
    Abstract: Disclosed is a method for the recombinant production of biofilaments, such as spider silk or insect fibroins, using transgenic animals which secrete the biofilaments in their milk and/or urine, and transgenic cells which secrete the biofilaments into culture media. Such a method is useful for producing large quantities of biofilament material. Also disclosed is a nucleic acid molecule for generating such transgenic animals.
    Type: Grant
    Filed: March 17, 1998
    Date of Patent: January 2, 2007
    Assignee: Nexia Biotechnologies, Inc.
    Inventors: Costas N. Karatzas, Jeffrey D. Turner, Anthoula Lazaris-Karatzas
  • Patent number: 7067713
    Abstract: The invention provides transgenic nonhuman mammals expressing C1 inhibitor in their milk. The C1 inhibitor is useful in treating patients with hereditary angioedema or patients requiring immunosuppression.
    Type: Grant
    Filed: January 31, 2001
    Date of Patent: June 27, 2006
    Assignee: Pharming Intellectual Property B.V.
    Inventors: Jan Henricus Nuijens, Henricus Antonius Van Veen, Frank Robert Pieper, Joris Jan Heus
  • Patent number: 7045676
    Abstract: A DNA sequence containing a gene encoding a protein, the gene being under the transcriptional control in the DNA sequence of a mammalian milk protein promoter which does not naturally control the transcription of the gene, such DNA sequence including DNA enabling secretion of the protein.
    Type: Grant
    Filed: August 31, 1992
    Date of Patent: May 16, 2006
    Assignee: GTC Biotherapeutics, Inc.
    Inventors: Katherine Gordon, Suzanne Groet
  • Patent number: 7045677
    Abstract: A process for the production of a peptide is disclosed, the process comprising expressing in the milk of a transgenic, non-human, placental mammal a fusion protein which comprises the peptide to be expressed linked to a fusion partner protein which is lysozyme. The fusion protein may be separate from the milk and cleaved to yield the target peptide. A transgenic, non-human, placental mammal whose genome incorporates a DNA molecule comprising a coding sequence encoding lysozyme coupled to a peptide is also described.
    Type: Grant
    Filed: December 21, 2001
    Date of Patent: May 16, 2006
    Assignee: Pharming Intellectual Property BV
    Inventors: Ian Robert Cottingham, Graham Edward McCreath
  • Patent number: 7030289
    Abstract: The present invention relates to the stabilization of milk from transgenic animals. In particular, the invention relates to the protection of proteins (e.g. fibrinogen) expressed in milk from transgenic animals by co-expression of a serine proteinase inhibitor (e.g., ?1-antitrypsin) in the milk of the transgenic animals.
    Type: Grant
    Filed: May 18, 2001
    Date of Patent: April 18, 2006
    Assignee: PPL Therapeutics (Scotland) Ltd
    Inventors: Ian Robert Cottingham, Graham Edward McCreath
  • Patent number: 7019193
    Abstract: This invention relates to transgenically produced human Antithrombin III (tgATIII). The human ATIII produced by the transgenic process of the present invention has a monosaccharide composition which comprises N-acetylgalactosamine (GalNAc) along with fucose, N-acetylglucosamine, galactose, mannose, and N-acetylneuraminic acid/N-glycolyneuraminic acid. The monosaccharide composition differs with that of plasma derived ATIII (phATIII). It has been found that tgATIII has an increased clearance rate when compared to phATIII.
    Type: Grant
    Filed: July 2, 2002
    Date of Patent: March 28, 2006
    Assignee: GTC Biotherapeutics, Inc.
    Inventors: Paul Ditullio, Harry M. Meade, Edward S. Cole
  • Patent number: RE42704
    Abstract: Materials and methods for producing fibrinogen in transgenic non-human mammals are disclosed. DNA segments encoding A?, B? and ? chains of fibrinogen are introduced into the germ line of a non-human mammal, and the mammal or its female progeny produces milk containing fibrinogen expressed from the introduced DNA segments. Non-human mammalian embryos and transgenic non-human mammals carrying DNA segments encoding heterologous fibrinogen polypeptide chains are also disclosed.
    Type: Grant
    Filed: January 15, 1999
    Date of Patent: September 13, 2011
    Assignee: Pharming Intellectual Property B.V.
    Inventors: Donna E. Prunkard, Donald C. Foster
  • Patent number: RE43691
    Abstract: The present invention relates to the use of a C1 inhibitor (C1INH) with shorter half-life than plasma-derived C1INH for the preparation of a medicament for the transient treatment of an individual. It relates to both therapeutic and prophylactic treatment. The method of the invention allows for the administration of C1INH at certain therapeutic levels for a concise pre-determined time span. Pharmaceutical compositions based on C1INH with shorter half-lives may be used both in situations where transient treatment is merely and advantage. The advantage of the use according to the invention is that an individual is not exposed to C1INH for longer than required, since the levels of the C1INH more rapidly subsides after administration has stopped. In contrast, levels of plasma-derived C1INH would remain elevated for a prolonged period of time.
    Type: Grant
    Filed: May 14, 2004
    Date of Patent: September 25, 2012
    Assignee: Pharming Intellectual Property B.V.
    Inventor: Johannes Henricus Nuijens